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Abstract
Background In high-quality cancer registration systems,
about one in eight incident cancers are second primary
cancers. This is due to a combination of careful diagnostic
ascertainment, shared genetic determinants, shared expo-
sure to environmental factors and consequences of treat-
ment for first cancer.
Methods We used data derived from the Swiss population-
based cancer Registries of Vaud and Neuchaˆtel, including
885,000 inhabitants.
Results Among 107,238 (52% males) first cancers occur-
ring between 1976 and 2010, a total of 126 second sarcomas
were observed through active and passive follow-up versus
68.2 expected, corresponding to a standardized incidence
ratio (SIR) of 1.85 (95 % CI 1.5–2.2). Significant excess
sarcoma risks were observed after skin melanoma
(SIR = 3.0), breast cancer (2.2), corpus uteri (2.7), testicular
(7.5), thyroid cancer (4.2), Hodgkin lymphoma (5.7) and
leukemias (4.0). For breast cancer, the SIR was 3.4 C5 years
after sarcoma diagnosis.
Conclusions The common denominator of these neo-
plasms is the utilization of radiotherapy in their manage-
ment. Some sarcomas following breast cancer may be due to
shared genetic components (i.e., in the Li–Fraumeni syn-
drome), as well as possibly to shared environmental factors,
with sarcomas, including overweight, selected dietary and
reproductive factors which are, however, too little defined
for any quantitative risk assessment.
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Introduction
Over recent years, in high-quality cancer registration sys-
tems, about one in eight to one in ten incident cancers are
second primary cancers. These are due to careful diagnostic
ascertainment following the diagnosis of a first primary
(synchronous cancers), but also to shared genetic deter-
minants as well as to exposure to environmental factors. In
addition, the occurrence of several neoplasms is influenced
by the therapies of the first cancer, including chemotherapy
and radiotherapy [1–4]. Colorectum, breast, prostate and
lymphomas are among the commonest sites with multiple
primary cancers [5].
Second sarcomas have been recognized as a growing issue
over the last few years [6]. Besides genetic components, little
is known, however, on the causes of sarcomas, and exposure to
ionizing radiation is one of the few established risk factors [7–
9]. Soft tissue sarcomas have also been associated with breast
and other cancers in the Li–Fraumeni syndrome [10].
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In order to quantify the risk of second sarcomas fol-
lowing another neoplasm (i.e., second sarcomas), we con-
sidered data from the cancer Registries of the Swiss
Cantons of Vaud and Neuchaˆtel [11–13].
Materials and methods
Data for the present report were abstracted from the Vaud
and Neuchaˆtel Swiss Registries’ files, which include all
incident cases of malignant neoplasms diagnosed in the
resident populations of these cantons (respectively, 713,000
and 172,000 inhabitants, according to the December 2010
National Census) [12, 13]. The registries are tumor-based,
and multiple primary malignancies found in the same person
are entered separately. Most cases are notified repeatedly and
from different institutions, thus improving the completeness
and accuracy of the registration. Both registries adhere to the
rules of registration for first and second primary cancers of
the International Agency for Research on Cancer (IARC)
[14] and have been included in the IARC Cancer Incidence in
Five Continents volumes since 1982 [15].
Population-based incidence data have been available
since 1974 and include information on demographic char-
acteristics (age, sex), primary site and morphology of the
tumor according to the standard International Classification
of Diseases for Oncology (ICD-O-1 and both ICD-O-1 and
ICD-O-3 since 2005) [16, 17] and the date of diagnostic
confirmation (histological or clinical diagnosis). No ade-
quate information was available on history of radiotherapy.
Both passive and active follow-ups are recorded, and
subsequent items of information are used to complete the
record of already registered cases. Information from the
death certificate is added to the registration file.
For the present analysis, after the exclusion of basal and
squamous cell carcinomas of the skin, 107,238 (52 % males)
first cancers occurring in patients diagnosed between 1976
and 2010 were considered. These subjects were followed up
for the occurrence of a sarcoma, emigration or death, for a
total of 453,792 person-years at risk. Calculation of expected
numbers of second sarcomas was based on sex-, age- and
calendar year-specific sarcoma incidence rates, multiplied
by the corresponding number of person-years at risk. The
significance of the observed/expected/ratios (standardized
incidence ratios, SIRs) and their corresponding 95 % con-
fidence intervals (CI) was based on the Poisson distribution,
or on exact test when required.
Results
Table 1 gives the number of registered first cancer cases
overall according to major cancer sites, the person-years at
risk and the number of second sarcomas.
Table 2 gives observed and expected numbers of sar-
comas following all cancers (excluding non-melanomatous
skin cancers) and following selected cancer sites, stratified
by sex and in both sexes combined. A total of 126 sarcomas
were observed following any previous cancer versus 68.2
expected, corresponding to a SIR of 1.85 (95 % CI
1.5–2.2). The SIR was 1.65 (1.2–2.1) in men and 2.03
(1.6–2.6) in women. There were 34 sarcomas following a
diagnosis of breast cancer versus 15.3 expected (SIR 2.22,
95 % CI 1.5–3.1). Significant excess sarcoma risks were
also observed following skin melanoma (11 cases, SIR
2.99, 95 % CI 1.5–5.3), corpus uteri (9 cases, SIR 2.72,
95 % 1.2–5.2), testicular cancer (6 cases, SIR 7.54, 95 %
CI 2.7–16.4), thyroid cancer (4 cases, SIR 4.24, 95 % CI
1.1–1.8), Hodgkin lymphoma (3 cases, SIR 5.68, 95 % CI
1.1–16.6) and leukemias (5 cases, SIR 3.98, 95 % CI
1.3–9.3). There were 14 sarcomas following colorectal
cancer versus 10.2 expected (SIR = 1.38), six following
lung cancer (SIR = 2.05), 13 following prostate cancer
(SIR = 1.13), and three following non-Hodgkin lympho-
mas (SIR = 1.3). None of these estimates was significant.
Following all other cancers combined, there were 18
observed sarcomas versus 15.5 expected, corresponding to
a SIR of 1.2 (95 % CI 0.7–1.8).
Table 3 gives observed and expected numbers of sar-
comas following colorectal, skin (melanoma), breast and
all cancers in strata of time since original cancer diagnosis
Table 1 Number of registered first cancer cases according to major
cancer sites, person-years at risk and number of second sarcomas
Vaud and Neuchaˆtel, Switzerland, incidence period 1976–2010
Site of first primary
(ICD-10)
Number
of first
primaries
Person-
years
at risk
Number of
second
sarcomas
Colorectum (C18–21) 13,186 61,510 14
Lung (C34) 12,665 19,502 6
Skin melanoma (C43) 4,884 26,808 11
Breast (C50) 17,329 113,037 34
Corpus uteri (C54) 2,882 21,426 9
Prostate (C61) 13,142 57,134 13
Testis (C62) 1,199 8,902 6
Thyroid (C73) 1,158 8,690 4
Hodgkin lymphoma (C81) 735 6,277 3
Non-Hodgkin lymphoma
(C82–85)
3,467 16,171 3
Leukemias (C91–95) 2,598 9,432 5
Other and unknown sitesa 33,990 104,902 18
Total, all sitesa 107,235 453,792 126b
Vaud and Neuchaˆtel, Switzerland, incidence period 1976–2010
a Non-melanomatous skin cancers excluded
b ICD morphological codes for sarcomas: 8800–4, 8810–32,
8850–70, 8890–1, 8900–20, 8930, 8951, 8990, 9020, 9120,
9130,9140, 9180–4, 9220, 9240, 9260, 9370, 9522, 9560, 9580
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(\5 vs. C5 years) and age at diagnosis of second sarcoma
(\70 vs. C70 years). The excess risk became significant
five or more years after breast cancer diagnosis (SIR 3.4,
95 % CI 2.2–4.9). No such pattern of risk with passing time
was observed for any other major cancer considered. With
reference to all cancers, the SIRs were 1.61 (95 % CI
1.2–2.1) under five years and 2.11 (95 % CI 1.6–2.7)
five years or more following the diagnosis of the first pri-
mary. With reference to age at diagnosis of second sarco-
mas, all the SIRs were somewhat higher at age C70, in the
absence, however, of heterogeneity. For all neoplasms, the
SIRs were 1.59 at age \70 versus 2.25 at age C70.
Discussion
The present, population-based study provides quantitative
evidence that the incidence of sarcomas is increased fol-
lowing a diagnosis of a number of cancer sites, including
breast cancer, skin melanoma, testicular, uterine and thy-
roid cancers, Hodgkin lymphoma and leukemias. The
common denominator of these neoplasms is the widespread
utilization of radiotherapy in their management. These
data, therefore, provide additional and definite evidence
that the risk of sarcomas is strongly associated with ion-
izing radiation [7, 8].
Some of the excess sarcomas, moreover, may be due to
shared genetic factors [5, 18]. Sarcomas, in fact, are one of
the components of the Li–Fraumeni syndrome, linked to
germline mutations of the TP53 tumor suppressor gene
[19], characterized in its classical form by sarcomas and
cancers of the breast, brain and adrenal glands. Shared
environmental factors, including immune suppression,
hormonal factors, height, body mass index (BMI) and
related aspects of diet [7, 20–23], may also have some role
on the excess sarcoma risk following another neoplasm.
Thus, immune suppression has been related to Kaposi’s
and also other types of cancers. In a cohort study linking
data on solid organ transplant recipients from the US Sci-
entific Registry of Transplant Recipients over the period
1987–2008 with 13 states and regional cancer registries,
and including 175,732 solid organ transplants, the SIRs
were 2.25 (95 % CI 1.74–2.87) for soft tissue sarcomas
including heart (65 cases) and 1.98 (95 % CI, 1.09–3.33)
for bone and joints (14 cases) [24]. Late age at first preg-
nancy and birth, a recognized risk factor for breast cancer,
has been associated with excess risk of sarcomas [20]. In an
Italian case–control study, the relative risk (RR) was over
three for BMI C30 versus \20 [22], and overweight and
obesity were related to colorectal, breast, endometrial
Table 2 Observed (O) and expected (E) sarcomas, and SIR, with
corresponding 95 % CI, by sex, among 107,238 patients diagnosed
with a first cancer. Vaud and Neuchaˆtel, Switzerland, incidence per-
iod 1976-2010
Site of first primary (ICD-
10)
Sex O E SIR (95 % CI)
Colorectum (C18–21) M&F 14 10.15 1.38 (0.7–2.3)
Lung (C34) M&F 6 2.93 2.05 (0.7–4.4)
Skin melanoma (C43) M&F 11 3.68 2.99(1.5–5.3)
Breast (C50) F 34 15.30 2.22(1.5–3.1)
Corpus uteri (C54) F 9 3.30 2.72 (1.2–5.2)
Prostate (C61) M 13 11.55 1.13 (0.6–1.9)
Testis (C62) M 6 0.80 7.54 (2.7–16.4)
Thyroid (C73) M&F 4 0.94 4.24 (1.1–1.8)
Hodgkin lymphoma (C81) M&F 3 0.53 5.68 (1.1–16.6)
Non-Hodgkin lymphoma
(C82–85)
M&F 3 2.30 1.31 (0.3–3.8)
Leukemias (C91–95) M&F 5 1.26 3.98 (1.3–9.3)
Other and unknown sitesa M&F 18 15.46 1.16 (0.7–1.8)
Total, all sitesa M 55 33.30 1.65 (1.2–2.1)
F 71 34.90 2.03 (1.6–2.6)
M&F 126b 68.21 1.85 (1.5–2.2)
a Non-melanomatous skin cancers excluded
b ICD morphological codes for sarcomas: 8800–4, 8810–32,
8850–70, 8890–1, 8900–20, 8930, 8951, 8990, 9020, 9120,
9130,9140, 9180–4, 9220, 9240, 9260, 9370, 9522, 9560, 9580
Table 3 Observed (O) and expected (E) sarcomas, and SIRs, with
corresponding 95 % CI, by time since diagnosis of selected first major
neoplasm and by age at diagnosis of second sarcoma. Vaud and
Neuchaˆtel, Switzerland, incidence period 1976–2010
Site of first primary
(ICD-10)
Time since first
neoplasm
Age at diagnosis of
second sarcoma
\5 years C5 years \70 years C70 years
O/E O/E O/E O/E
SIR SIR SIR SIR
(95 %
CI)
(95 %
CI)
(95 % CI) (95 % CI)
Colorectum
(C18–21)
7/5.3 7/4.8 6/5.3 8/4.9
1.32 1.45 1.14 1.64
(0.5–2.7) (0.6–3.0) (0.4–2.5) (0.7–3.2)
Skin melanoma
(C43)
6/1.7 5/2.0 6/2.5 5/1.2
3.50 2.54 2.38 4.33
(1.3–7.6) (0.8–5.9) (0.9–5.2) (1.4–10.1)
Breast (C50) 7/7.3 27/8.1 18/10.5 16/4.8
0.97 3.35 1.71 3.36
(0.4–2.0) (2.2–4.9) (1.0–2.7) (1.9–5.5)
Total, all sitesa 58/36.0 68/32.2 66/41.6 60/26.6
1.61 2.11 1.59 2.25
(1.2–2.1) (1.6–2.7) (1.2–2.1) (1.7–2.9)
a Non-melanomatous skin cancers excluded
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cancer, lymphoma and several other neoplasms [25–28]. In
a companion study [21], whole grain was inversely related
to the risk of soft tissue sarcomas, whereas selected foods
rich in animal fats tended to be positively associated. This
is compatible with our knowledge on favorable and unfa-
vorable dietary patterns on the risk of several neoplasms
[29, 30]. These factors, however, are too poorly defined
and quantified in relation to sarcoma risk to provide any
clue for the interpretation of the present results.
A major advantage of these Swiss datasets is that, in the
populations considered, there is a long tradition of valid
and accurate cancer registration (confirmed by the inclu-
sion of incidence data in the last seven quinquennial issues
of the IARC/WHO series Cancer Incidence in five Conti-
nents) [12, 13], as well as of systematic examination of all
surgically treated lesions, including skin melanomas [11,
31], thus adding validity to the present results.
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